Agronomics Limited
27 November 2024
Agronomics Ltd
("Agronomics" or the "Company")
All G Receives Approval for
Sale of Recombinant Bovine Lactoferrin in China
Agronomics (LSE: ANIC), a leading
listed company in the field of cellular agriculture, is delighted
to announce that its portfolio company, All G Co Holdings Pty
Limited ("All G"), is the first company in the world to receive
regulatory clearance for the sale of recombinant bovine lactoferrin
in China.
All G is an Australian-based
biotechnology company at the forefront of using precision
fermentation to develop high-value, animal-free proteins for use in
a variety of markets - ranging from functional foods, medical
nutrition and infant nutrition.
Lactoferrin, a whey protein found in
human and cow milk, is highly sought-after for its numerous
functional benefits, including enhancing gut function, iron
absorption and providing antimicrobial and anti-inflammatory
benefits. However, due to its low concentration in cow's milk, it
is expensive to produce and yields only limited quantities,
creating a major opportunity for alternative protein
producers.
China represents one of the largest
consumers of lactoferrin globally, driven by a growing demand for
functional foods and health-conscious consumers. The approval
allows for the sale of All G's product into a specific target
market which will be disclosed closer to the time of market entry.
The company is simultaneously progressing with regulatory approval
for the use of its lactoferrin in infant formula, which is expected
in 2025.
This approval is significant for All
G, as it will allow the company to bring in initial revenue streams
in advance of its Series B fund raise. Revenues are projected to be
at positive margins as All G aims to produce at or below price
parity compared with conventionally produced lactoferrin. All G
intends to release its first lactoferrin product in 2025 and plans
to receive approval for its products in the US, Australia, New
Zealand, and Japan.
All G's regulatory approval in China
comes after only three years of operations. To date, All G has
raised AU$ 45 million and was named Food & Beverage Startup of
the Year by the Food and Beverage Accelerator in Australia for its
work in changing dairy protein production. Agronomics has
invested AU$ 15 million into All G since inception, which is
currently carried at £7.9 million as of 30 June 2024.
Commenting on the announcement, Jan Pacas, All G CEO,
said: "This approval is a great moment for All G as we lead the way
in precision fermentation technology. Lactoferrin is one of the
most valuable and functional proteins in the world. Our technology
unlocks its potential, and this is just the beginning - our
recombinant human lactoferrin is progressing rapidly, with many
other products in the pipeline."
Jim
Mellon, Agronomics' Executive Chair, added:
"Today's
announcement is another testament to the
strength of the Agronomics portfolio. All G is one of the leading
technology companies developing animal-free proteins and achieving
regulatory approval for Lactoferrin in China - the world's largest
market - is an exciting step for the industry. More importantly, it
provides a platform from which All G can bring other key products
to market at competitive prices."
About All G
All G is a Sydney-based
biotechnology company that is at the forefront of precision
fermentation, developing high-value, animal-free proteins for use
in functional foods, medical nutrition and infant nutrition.
Founded in 2020 by CEO Jan Pacas, the company has successfully
raised AU$ 45 million and is planning to launch its first
lactoferrin product in 2025.
About
Agronomics
Agronomics is a leading
London-listed company focussing on investment opportunities within
the field of cellular agriculture. The Company has established a
portfolio of over 20 companies in this rapidly advancing sector. It
seeks to invest in companies owning technologies with defensible
intellectual property that offer new ways of producing food and
materials with a focus on products historically derived from
animals. These technologies are driving a major disruption in
agriculture, offering solutions to improve sustainability, as well
as addressing human health, animal welfare and environmental
damage. This disruption will decouple supply chains from the
environment and animals and improve food security for the world's
expanding population. A full list of Agronomics' portfolio
companies is available at https://agronomics.im/.
For further information please
contact:
Agronomics
Limited
|
Beaumont Cornish
Limited
|
Canaccord Genuity
Limited
|
Cavendish Securities
Plc
|
Peterhouse Capital
Limited
|
SEC Newgate
|
The
Company
|
Nomad
|
Joint
Broker
|
Joint
Broker
|
Joint
Broker
|
Public
Relations
|
Jim
Mellon
Denham
Eke
|
Roland
Cornish
James
Biddle
|
Andrew
Potts
Harry
Pardoe
Alex
Aylen (Head of Equities)
|
Giles
Balleny
Michael
Johnson
|
Lucy
Williams
Charles
Goodfellow
|
Bob
Huxford
Anthony
Hughes
|
+44 (0)
1624 639396
info@agronomics.im
|
+44 (0)
207 628 3396
|
+44 (0)
207 523 8000
|
+44 (0)
207 397 8900
|
+44 (0)
207 469 0936
|
agronomics@secnewgate.co.uk
|
Nominated
Adviser
Beaumont Cornish Limited ("Beaumont
Cornish") is the Company's Nominated Adviser and is authorised and
regulated by the FCA. Beaumont Cornish's responsibilities as the
Company's Nominated Adviser, including a responsibility to advise
and guide the Company on its responsibilities under the AIM Rules
for Companies and AIM Rules for Nominated Advisers, are owed solely
to the London Stock Exchange. Beaumont Cornish is not acting for
and will not be responsible to any other persons for providing
protections afforded to customers of Beaumont Cornish nor for
advising them in relation to the proposed arrangements described in
this announcement or any matter referred to in it.